Pulmonx Corp
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
LUNG$2.800.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · Accumulated Deficit · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balances at December 31, 2021 | 36,931,762 | $37 | $482,885 | $1,712 | $(291,395) | $193,239 |
| Issuance of common stock upon vesting of restricted stock units | 251,133 | — | — | — | — | — |
| Issuance of common stock upon exercise of stock options | 297,463 | 1 | 634 | — | — | 635 |
| Issuance of shares pursuant to Employee Stock Purchase Plan | 89,666 | — | 1,942 | — | — | 1,942 |
| Repurchase of early exercised common stock options | (14,459) | — | — | — | — | — |
| Change in shares subject to repurchase | — | — | 227 | — | — | 227 |
| Stock-based compensation expense | — | — | 17,024 | — | — | 17,024 |
| Currency translation adjustment | — | — | — | 150 | — | 150 |
| Change in unrealized losses on marketable securities | — | — | — | (287) | — | (287) |
| Net loss | — | — | — | — | (58,923) | (58,923) |
| Balances at December 31, 2022 | 37,555,565 | 38 | 502,712 | 1,575 | (350,318) | 154,007 |
| Issuance of common stock upon vesting of restricted stock units | 672,180 | 1 | (1) | — | — | — |
| Issuance of common stock upon exercise of stock options | 137,902 | — | 314 | — | — | 314 |
| Issuance of shares pursuant to Employee Stock Purchase Plan | 150,842 | — | 1,184 | — | — | 1,184 |
| Repurchase of early exercised common stock options | (106) | — | — | — | — | — |
| Change in shares subject to repurchase | — | — | 144 | — | — | 144 |
| Stock-based compensation expense | — | — | 22,444 | — | — | 22,444 |
| Currency translation adjustment | — | — | — | 671 | — | 671 |
| Change in unrealized gains on marketable securities | — | — | — | 394 | — | 394 |
| Net loss | — | — | — | — | (60,843) | (60,843) |
| Balances at December 31, 2023 | 38,516,383 | $39 | $526,797 | $2,640 | $(411,161) | $118,315 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.